Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C

American Journal of Transplantation

Volumn 13, Issue 6, 2013, Pages 1601-1605

  Fontana, R J ^a   Hughes, E A ^b   Bifano, M ^b   Appelman, H ^c   Dimitrova, D ^b   Hindes, R ^d   Symonds, W T ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

Calcineurin inhibitors; direct acting antiviral agents; hepatitis C; polymerase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DACLATASVIR; FUROSEMIDE; INTERFERON; ISOPHANE INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE; PEGINTERFERON; PREDNISONE; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; VIRUS RNA; VITAMIN D;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHOLESTATIC HEPATITIS; CYTOPLASM; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER FAILURE; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VIRUS REPLICATION;

CHOLESTASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RNA, VIRAL; TRANSPLANTATION, HOMOLOGOUS; URIDINE MONOPHOSPHATE;

EID: 84878475234     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12209     Document Type: Article

References (24)

1. Verna ED, Brown RS., Hepatitis C virus and liver transplantation. Clin Liv Dis 2006; 10: 919-929.
2. Forman LM, Lewis JD, Berlin JA, Feldman HL, Lucey MR., The association between hepatitis C infection and survival after liver transplantation. Gastroenterology 2002; 122: 889-896.
3. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177.
4. Guillouche P, Feray C., Systematic review: Anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163-174.
5. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated Interferon. Gastroenterology 2012; 142: 1132-1139.
6. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-1630.
7. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X., Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
8. Coilly A, Roche B, Dumortier J, et al. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation: A first multicentric experience (Abstract). Hepatology 2012; 56 (Suppl 1): A#9.
9. Pungapong S, Murphy JL, Henry TM, et al. Preliminary experience using telaprevir with peginterferon and ribavirin for treatment of HCV genotype 1 after liver transplantation (Abstract). Hepatology 2012; 56 (Suppl 1): A#10.
10. Lok ASF, Gardiner DF, Lawitz E, et al. Preliminary study of two oral antiviral agents for hepatitis C genotype 1. NEJM 2012; 366: 216-224.
11. Pol S, Ghalib RH, Rustgi V, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: A randomized, parallel-group, double-blind, placebo controlled, dose finding, phase 2a. Trial Lancet Inf Dis 2012; 12: 671-677.
12. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. NEJM 2013; 368: 34-44.
13. Hassanein T, Lawitz E, Crespo I, et al. Once daily sofosbuvir (GS 7977) plus PEG/RBV: High early response rates are maintained during post-treatment follow-up in treatment naïve patient with HCV Genotype 1, 4 and 6 infection in the ATOMIC study (Abstract). Hepatology 2012; 56 (Suppl 1): #230.
14. Bifano M, Sevinsky H, Persson A, et al. Daclatasvir (DCV; BMS-790052) has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects (Abstract). Hepatology 2011; 54 (Suppl 1): A #1340.
15. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT., NO clinically significant pharmacokinetic drug-drug interactions between Sofosbuvir (GS-7977) and the immunosuppressants cyclosporine A or Tacrolimus in health volunteers (Abstract). Hepatology 2012; 56 (Suppl 1): A1869.
16. Narang TK, Ahrens W, Russo MW., Post liver transplant cholestatic hepatitis C: AA systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228-1235.
17. Selzner N, Guindi M, Renner EL, Berenguer M., Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-217.
18. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465.
19. Veldt BJ, Poterucha JJ, Watt KDS, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent HCV infection. Am J Transpl 2008; 8: 1-8.
20. Sulkowski MJ, Gardiner D, Rodriguez-Torres M, et al. High rate of sustained virological response with all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), +/- ribavirin, in treatment naïve patients with chronically infected with HCV genotype 1, 2 and 3 (Abstract). Hepatology 2012; 56: LB#2.
21. Jacobson IM, Dimitrova DI, Hughes EA, et al. Safety profile of Daclatasvir in combination with peginterferon alfa and ribavirin in 1100 patients with chronic HCV infection treated in Phase 2 studies. J Hepatol 2013; (Accepted EASL Abstract).
22. Jacobson IM, Lawitz E, Lalezari J, et al. GS 0-7977 400 mg q d safety and tolerability in the over 500 patients treated for at least 12 weeks (Abstract). J Hepatol 2012; 56: S441.
23. Cornpropst MT, Denning JM, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 2012; 56: S431.
24. Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M., Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver Retransplantation. Liver Transpl 2012; 18: 1053-1059.